Document is current
Any future updates will be listed below
-
Authors
Chawana, Tariro D.
Walsh, Stephen R.
Stranix-Chibanda, Lynda
Chirenje, Zvavahera M.
Yu, Chenchen
Zhang, Lily
Seaton, Kelly E.
Heptinstall, Jack
Zhang, Lu
Paez, Carmen A.
Gamble, Theresa
Karuna, Shelly T.
Andrew, Philip
Hanscom, Brett
Sobieszczyk, Magdalena E.
Edupuganti, Srilatha
Gay, Cynthia L.
Mannheimer, Sharon B.
Hurt, Christopher B.
Stephenson, Kathryn E.
Polakowski, Laura L.
Spiegel, Hans
Yacovone, Margaret
Regenold, Stephanie
Yen, Catherine
Baumblatt, Jane AG.
Gama, Lucio
Barouch, Dan H.
Piwowar-Manning, Estelle
Koup, Richard A.
Tomaras, Georgia D.
Hyrien, Ollivier
Roxby, Alison C.
Huang, Yunda
,
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (UM1 AI068614)
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 11 February 2025
First Online: 19 February 2025
Declarations
:
: HVTN 127/HPTN 087, HVTN 130/HPTN 089 and HVTN 136/HPTN 092 were approved by the Institutional Review Boards of each participating clinical research site and by the Fred Hutchinson Cancer Center. The original trials were registered with Clinical Trials.gov (HVTN 127/HPTN 087- NCT03387150 (29 December 2017); HVTN 130/HPTN 089- NCT03928821 (26 April 2019); HVTN 136/HPTN 092- NCT04212091 (26 December 2019). Research was conducted according to the Declaration of Helsinki. Ethical review and approval for this sub-study were waived because all studies were reviewed and approved individually, and participants agreed to use of their anonymized samples for future research. This sub-study was approved by the HVTN Scientific Review Committee and HPTN Manuscript Review Committee. All participants provided written informed consent in their primary studies including consent for subsequent use of their samples and data.
: All co-authors consent to publication of this manuscript.
: S.R.W. has received institutional funding from the National Institute of Allergy and Infectious Diseases/National Institutes of Health; and institutional grants or contracts from Sanofi Pasteur, Janssen Vaccines/Johnson & Johnson, Moderna Tx, Pfizer, Vir Biotechnology, and Worcester HIV Vaccine; has participated on data safety monitoring or advisory boards for Janssen Vaccines/Johnson & Johnson and BioN-Tech; and his spouse holds stock/stock options in Regeneron Pharmaceuticals. C.L.G. has received institutional grants or contracts from the NIH, ViiV and Gilead. L.L.P., M.Y., S.R., and C.Y. are/were Medical Officers with the National Institute of Allergy and Infectious Diseases (NIAID)/NIH and L.G. and R.K. are/were Staff Scientists with NIAID/NIH. The funder had no other role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors declare no conflict of interest.
